JP7177041B2 - 血小板様細胞を含有する血液の血小板に富む画分を用いて成体細胞をプログラミングするための組成物および方法 - Google Patents

血小板様細胞を含有する血液の血小板に富む画分を用いて成体細胞をプログラミングするための組成物および方法 Download PDF

Info

Publication number
JP7177041B2
JP7177041B2 JP2019511844A JP2019511844A JP7177041B2 JP 7177041 B2 JP7177041 B2 JP 7177041B2 JP 2019511844 A JP2019511844 A JP 2019511844A JP 2019511844 A JP2019511844 A JP 2019511844A JP 7177041 B2 JP7177041 B2 JP 7177041B2
Authority
JP
Japan
Prior art keywords
cells
platelet
cell
rich fraction
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530438A5 (https=
JP2019530438A (ja
Inventor
ヨン ジャオ
Original Assignee
ハッケンサック ユニヴァーシティ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハッケンサック ユニヴァーシティ メディカル センター filed Critical ハッケンサック ユニヴァーシティ メディカル センター
Publication of JP2019530438A publication Critical patent/JP2019530438A/ja
Publication of JP2019530438A5 publication Critical patent/JP2019530438A5/ja
Application granted granted Critical
Publication of JP7177041B2 publication Critical patent/JP7177041B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3616—Blood, e.g. platelet-rich plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
JP2019511844A 2016-08-29 2017-08-28 血小板様細胞を含有する血液の血小板に富む画分を用いて成体細胞をプログラミングするための組成物および方法 Active JP7177041B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662380913P 2016-08-29 2016-08-29
US62/380,913 2016-08-29
US201762520241P 2017-06-15 2017-06-15
US62/520,241 2017-06-15
PCT/US2017/048907 WO2018044795A1 (en) 2016-08-29 2017-08-28 Compositions and methods for programming adult cells with platelet rich fraction of blood containing platelet-like cells

Publications (3)

Publication Number Publication Date
JP2019530438A JP2019530438A (ja) 2019-10-24
JP2019530438A5 JP2019530438A5 (https=) 2020-10-01
JP7177041B2 true JP7177041B2 (ja) 2022-11-22

Family

ID=61241132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019511844A Active JP7177041B2 (ja) 2016-08-29 2017-08-28 血小板様細胞を含有する血液の血小板に富む画分を用いて成体細胞をプログラミングするための組成物および方法

Country Status (9)

Country Link
US (1) US10729730B2 (https=)
EP (1) EP3504320A4 (https=)
JP (1) JP7177041B2 (https=)
KR (1) KR102396303B1 (https=)
CN (1) CN110023488A (https=)
AU (1) AU2017321300B2 (https=)
CA (1) CA3033750A1 (https=)
IL (1) IL264815B2 (https=)
WO (1) WO2018044795A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2788472T (lt) 2011-12-06 2019-04-10 Astellas Institute For Regenerative Medicine Kryptingos diferenciacijos būdas, skirtas ragenos endotelio ląstelių gamybai
JP2021509812A (ja) 2018-01-05 2021-04-08 プレートレット バイオジェネシス， インコーポレイテッド 巨核球を産生するための組成物および方法
JP2021526556A (ja) 2018-05-30 2021-10-07 ダイレクト バイオロジクス エルエルシー 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞（ｍｓｃ）の調製物を含む助剤、ならびにその使用方法
AU2019291955A1 (en) 2018-06-29 2021-02-18 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
AU2019305092A1 (en) 2018-07-19 2021-03-11 Platelet Biogenesis, Inc. Stacked recirculating bioreactor
CN108888636A (zh) * 2018-08-14 2018-11-27 东营凤起生物科技发展有限公司 一种治疗糖尿病和动脉粥样硬化的方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3863650A4 (en) * 2018-10-10 2022-09-14 North Carolina State University PRESENTATION BLISTERS OF PD-L1 TO REVERSE NEW ONSET OF TYPE 1 DIABETES
WO2020142769A1 (en) * 2019-01-04 2020-07-09 Kenneth Allen Pettine Isolation and use of autogenous platelet derived exosomes
AU2020265737A1 (en) * 2019-05-01 2021-12-02 Immunebridge Inc. Methods of making oligopotent and unipotent precursors
AU2020277774A1 (en) * 2019-05-22 2021-12-09 Thankstem S.R.L. Method for expanding adult stem cells from whole blood
EP4103694A4 (en) * 2020-02-14 2024-03-20 Hackensack Meridian Health, Inc. TREATMENT MITOCHONDRIA FROM THROMBOCYTES AND METHOD FOR GENERATING MULTIPOTENT CELLS
US12590310B2 (en) 2020-04-22 2026-03-31 Direct Biologics, Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
CA3178268A1 (en) 2020-05-11 2021-11-18 Jonathan Thon Compositions and methods related to megakaryocyte-derived extracellular vesicles
CN115917316B (zh) * 2020-06-12 2025-10-24 新加坡科技研究局 嗜中性粒细胞祖细胞及相关方法和用途
CN112156111B (zh) * 2020-08-31 2022-10-18 中南大学湘雅三医院 脐血血小板线粒体在制备治疗自身免疫疾病药物中的应用
JP2024518770A (ja) 2021-04-26 2024-05-02 ストーム バイオ インコーポレイテッド ファンコニ貧血のための巨核球由来細胞外小胞に関する組成物及び方法
JPWO2023079655A1 (https=) * 2021-11-04 2023-05-11
CN114990164B (zh) * 2022-06-16 2023-12-05 北京大学 中介体复合物亚基抑制剂及其应用
WO2024086955A1 (es) * 2022-10-26 2024-05-02 Cells For Cells S.A. Efecto inmunosupresor sobre linfocitos t cd4+ de una composición enriquecida en mitocondrias circulantes
WO2025017354A1 (en) * 2023-07-14 2025-01-23 Id Medical Group Australia Pty Ltd Isolated autological double-derived cell population enriched with mesenchymal stem cells (mscs) and methods for obtaining and using the same
CN116836920B (zh) * 2023-08-21 2024-05-24 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 一种无血清培养基及其制备间充质干细胞的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317439A1 (en) 2006-08-21 2009-12-24 Antoine Turzi Cell Preparations for Extemporaneous Use, Useful for Healing and Rejuvenation In Vivo
US20100129440A1 (en) 2006-10-18 2010-05-27 Yong Zhao Embryonic-like stem cells derived from adult human peripheral blood and methods of use
JP2013522186A (ja) 2010-03-11 2013-06-13 アントワーヌ テュージィ 創傷治癒剤組成物を調製するための方法、管および器具
JP2014520523A (ja) 2011-07-06 2014-08-25 セル セラピー リミテッド 中胚葉系列の前駆細胞
US20140356893A1 (en) 2013-06-04 2014-12-04 Allan Mishra Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098646A1 (en) 2003-05-12 2004-11-18 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317439A1 (en) 2006-08-21 2009-12-24 Antoine Turzi Cell Preparations for Extemporaneous Use, Useful for Healing and Rejuvenation In Vivo
US20100129440A1 (en) 2006-10-18 2010-05-27 Yong Zhao Embryonic-like stem cells derived from adult human peripheral blood and methods of use
JP2013522186A (ja) 2010-03-11 2013-06-13 アントワーヌ テュージィ 創傷治癒剤組成物を調製するための方法、管および器具
JP2014520523A (ja) 2011-07-06 2014-08-25 セル セラピー リミテッド 中胚葉系列の前駆細胞
US20140356893A1 (en) 2013-06-04 2014-12-04 Allan Mishra Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BMC Medicine，2012年，10, 3，pp.1-11
Cell research，2009年，19(4)，429-438
Gastroenterology，2005年，128(7)，1774-1786

Also Published As

Publication number Publication date
CN110023488A (zh) 2019-07-16
KR102396303B1 (ko) 2022-05-09
WO2018044795A1 (en) 2018-03-08
IL264815B1 (en) 2024-05-01
IL264815B2 (en) 2024-09-01
EP3504320A4 (en) 2020-04-15
AU2017321300B2 (en) 2022-11-17
KR20190040333A (ko) 2019-04-17
US20180055891A1 (en) 2018-03-01
JP2019530438A (ja) 2019-10-24
AU2017321300A9 (en) 2019-08-01
EP3504320A1 (en) 2019-07-03
IL264815A (en) 2019-03-31
WO2018044795A9 (en) 2019-03-07
AU2017321300A1 (en) 2019-02-28
CA3033750A1 (en) 2018-03-08
US10729730B2 (en) 2020-08-04

Similar Documents

Publication Publication Date Title
JP7177041B2 (ja) 血小板様細胞を含有する血液の血小板に富む画分を用いて成体細胞をプログラミングするための組成物および方法
AU2022287675B2 (en) Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans
EP3572502B1 (en) Method for producing cd8alpha +beta + cytotoxic t cells
EP4497822A1 (en) Method for producing regulatory t cells
JP2025160223A (ja) ヒト多能性幹細胞からバイオエンジニアリングされた胸腺オルガノイド
CN112513255A (zh) 介由iPS细胞制造再生T细胞群体的方法
US20250154458A1 (en) Methods for Making, Compositions Comprising, and Methods of Using Rejuvenated T Cells
AU2023353929A1 (en) T cell production method
US12091684B2 (en) Platelet-derived mitochondria treatment and method of generating multipotent cells
CN113939302A (zh) 医药组合物
HK40009594A (en) Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans
WO2024050534A2 (en) In vitro generated hematopoietic stem progenitor cells and t cells and methods of making and using the same
WO2025151477A1 (en) Methods of producing rejuvenated human somatic cells, compositions, and methods of use
CN116615209A (zh) 制备再生t细胞的方法、包含再生t细胞的组合物及使用再生t细胞的方法
HK1253871A1 (en) Methods and compositions for inducing hematopoietic cell differentiation
HK1253871B (en) Methods and compositions for inducing hematopoietic cell differentiation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200817

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220714

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221110

R150 Certificate of patent or registration of utility model

Ref document number: 7177041

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250